• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Reflections on 2024’s Progress in R/R CLL

Opinion
Video

Panelists discuss how the relapsed/refractory chronic lymphocytic leukemia treatment landscape evolved significantly in 2024 with expanded Bruton tyrosine kinase inhibitor options, growing real-world evidence for newer agents, and emerging combination strategies, while expressing optimism for future advances in personalized therapy approaches and novel drug development.

Related Videos
Dr Rebecca Haberman
2 experts in this video
2 experts in this video
Dr Michael Bernstein
1 expert is featured in this series.
5 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.